|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
BR0313059B8
(pt)
|
2002-07-29 |
2021-07-27 |
Rigel Pharmaceuticals |
composto, e, composição farmacêutica
|
|
CN102358738A
(zh)
|
2003-07-30 |
2012-02-22 |
里格尔药品股份有限公司 |
2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
|
|
AU2011253635B2
(en)
*
|
2003-09-17 |
2014-10-30 |
Janssen Pharmaceutica, N.V. |
Fused heterocyclic compounds
|
|
DE602004019118D1
(de)
|
2003-09-17 |
2009-03-05 |
Janssen Pharmaceutica Nv |
Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
|
|
WO2005068473A1
(en)
*
|
2003-12-17 |
2005-07-28 |
Sgx Pharmaceuticals, Inc. |
Bicyclic pyrazolo-fused compounds as protein kinase modulators
|
|
WO2005123111A2
(en)
*
|
2004-06-21 |
2005-12-29 |
Exelixis, Inc. |
Maxs as modifiers of the axin pathway and methods of use
|
|
CA2581623A1
(en)
|
2004-09-23 |
2006-03-30 |
Reddy Us Therapeutics, Inc. |
Novel pyridine compounds, process for their preparation and compositions containing them
|
|
JP4801096B2
(ja)
*
|
2005-01-19 |
2011-10-26 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
|
|
US20070203161A1
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
EP1904457B1
(en)
|
2005-06-08 |
2017-09-06 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2008079521A2
(en)
*
|
2006-11-01 |
2008-07-03 |
Vertex Pharmaceuticals Incorporated |
Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
|
|
JP2009528295A
(ja)
|
2006-02-24 |
2009-08-06 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
Ｊａｋ経路の阻害のための組成物および方法
|
|
US8969295B2
(en)
*
|
2006-04-14 |
2015-03-03 |
Massachusetts Institute Of Technology |
Identifying and modulating molecular pathways that mediate nervous system plasticity
|
|
EP2044056B1
(en)
*
|
2006-07-14 |
2012-08-22 |
Novartis AG |
Pyrimidine derivatives as alk-5 inhibitors
|
|
US20100137398A1
(en)
*
|
2007-05-04 |
2010-06-03 |
Novartis Ag |
Use of hdac inhibitors for the treatment of gastrointestinal cancers
|
|
HUE030912T2
(en)
|
2008-02-15 |
2017-06-28 |
Rigel Pharmaceuticals Inc |
Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
MX2010011463A
(es)
|
2008-04-16 |
2011-06-03 |
Portola Pharm Inc |
2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
|
|
JP2011518219A
(ja)
|
2008-04-22 |
2011-06-23 |
ポートラ ファーマシューティカルズ， インコーポレイテッド |
タンパク質キナーゼの阻害剤
|
|
JP5063815B2
(ja)
*
|
2008-11-25 |
2012-10-31 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
|
|
JP2012517448A
(ja)
*
|
2009-02-11 |
2012-08-02 |
リアクション バイオロジー コープ． |
選択的キナーゼ阻害剤
|
|
US8663210B2
(en)
|
2009-05-13 |
2014-03-04 |
Novian Health, Inc. |
Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
|
|
JO3030B1
(ar)
*
|
2009-06-26 |
2016-09-05 |
Galapagos Nv |
مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
|
|
JP2012533553A
(ja)
*
|
2009-07-15 |
2012-12-27 |
アボット・ラボラトリーズ |
ピロロピリジン系キナーゼ阻害薬
|
|
CA2768543C
(en)
*
|
2009-07-28 |
2017-06-20 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
JP2013503189A
(ja)
*
|
2009-08-28 |
2013-01-31 |
アレイ バイオファーマ、インコーポレイテッド |
Ｒａｆ阻害化合物およびその使用方法
|
|
UY33213A
(es)
*
|
2010-02-18 |
2011-09-30 |
Almirall Sa |
Derivados de pirazol como inhibidores de jak
|
|
EP2635557A2
(en)
|
2010-11-01 |
2013-09-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
|
SG11201402570QA
(en)
|
2011-11-23 |
2014-06-27 |
Portola Pharm Inc |
Pyrazine kinase inhibitors
|
|
WO2013113762A1
(en)
|
2012-01-31 |
2013-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
|
|
ES2694681T3
(es)
*
|
2012-03-29 |
2018-12-26 |
The Trustees Of Columbia University In The City Of New York |
Métodos para tratar trastornos de pérdida capilar
|
|
SI3459942T1
(sl)
|
2012-04-24 |
2021-05-31 |
Vertex Pharmaceuticals Incorporated |
Inhibitorji DNA-PK
|
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
|
US9676756B2
(en)
|
2012-10-08 |
2017-06-13 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
HUE041544T2
(hu)
|
2013-03-12 |
2019-05-28 |
Vertex Pharma |
DNS-PK inhibitorok
|
|
PT3424920T
(pt)
|
2013-10-17 |
2020-07-07 |
Vertex Pharma |
Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk
|
|
RU2016141934A
(ru)
*
|
2014-04-04 |
2018-05-07 |
Сирос Фармасьютикалз, Инк. |
Ингибиторы циклин-зависимой киназы 7 (cdk7)
|
|
US9527845B2
(en)
*
|
2014-12-30 |
2016-12-27 |
Novira Therapeutics, Inc. |
Derivatives and methods of treating hepatitis B infections
|
|
US10045981B2
(en)
|
2015-11-24 |
2018-08-14 |
Jakpharm, Llc |
Selective kinase inhibitors
|
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
|
JP2019529475A
(ja)
|
2016-09-27 |
2019-10-17 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
|
|
US10759865B2
(en)
|
2017-08-22 |
2020-09-01 |
Eyal Levit |
Treatment of diabetes mellitus
|
|
WO2019046316A1
(en)
*
|
2017-08-28 |
2019-03-07 |
Acurastem Inc. |
PIKFYVE KINASE INHIBITORS
|
|
CN108586341B
(zh)
*
|
2018-05-25 |
2020-05-08 |
天津商业大学 |
酰胺类化合物和其药用盐及其制备方法和药物用途
|
|
EP3942045A1
(en)
|
2019-03-21 |
2022-01-26 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
US20220177978A1
(en)
|
2019-04-02 |
2022-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
US20220202820A1
(en)
|
2019-04-16 |
2022-06-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
|
|
EP4054579A1
(en)
|
2019-11-08 |
2022-09-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
CN114605390B
(zh)
*
|
2020-12-04 |
2024-08-16 |
上海凌达生物医药有限公司 |
具有cdk激酶抑制活性的化合物、其药物组合物和用途
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
EP4526469A1
(en)
|
2022-05-16 |
2025-03-26 |
Institut National de la Santé et de la Recherche Médicale |
Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|
|
WO2026093435A1
(en)
|
2024-10-31 |
2026-05-07 |
Institut National de la Santé et de la Recherche Médicale |
Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer
|